{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:41:01Z","timestamp":1794944461474,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EHA Junior Research Grant","award":["3978026"],"award-info":[{"award-number":["3978026"]}]},{"name":"Italian Ministry of Health - PRIN","award":["2020Z22PM7"],"award-info":[{"award-number":["2020Z22PM7"]}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["Fondazione IRCCS-CG, RC 175\/05"],"award-info":[{"award-number":["Fondazione IRCCS-CG, RC 175\/05"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","award":["COINOR"],"award-info":[{"award-number":["COINOR"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Iron homeostasis and dyserythropoiesis are poorly investigated in pyruvate kinase deficiency (PKD), the most common glycolytic defect of erythrocytes. Herein, we studied the main regulators of iron balance and erythropoiesis, as soluble transferrin receptor (sTfR), hepcidin, erythroferrone (ERFE), and erythropoietin (EPO), in a cohort of 41 PKD patients, compared with 42 affected by congenital dyserythropoietic anemia type II (CDAII) and 50 with hereditary spherocytosis (HS). PKD patients showed intermediate values of hepcidin and ERFE between CDAII and HS, and clear negative correlations between log-transformed hepcidin and log-EPO (Person\u2019s r correlation coefficient\u2009=\u2009\u2009\u2212\u20090.34), log-hepcidin and log-ERFE (r\u2009=\u2009\u2009\u2212\u20090.47), and log-hepcidin and sTfR (r\u2009=\u2009\u2009\u2212\u20090.44). sTfR was significantly higher in PKD; EPO levels were similar in PKD and CDAII, both higher than in HS. Finally, genotype\u2013phenotype correlation in PKD showed that more severe patients, carrying non-missense\/non-missense genotypes, had lower hepcidin and increased ERFE, EPO, and sTFR compared with the others (missense\/missense and missense\/non-missense), suggesting a higher rate of ineffective erythropoiesis. We herein investigated the main regulators of systemic iron homeostasis in the largest cohort of PKD patients described so far, opening new perspectives on the molecular basis and therapeutic approaches of this disease.<\/jats:p>","DOI":"10.1038\/s41598-023-31571-2","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:03:01Z","timestamp":1678968181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency"],"prefix":"10.1038","volume":"13","author":[{"given":"Anna","family":"Zaninoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Andolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Paola","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Eleni","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Vercellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Iolascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"31571_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ejh.13424","volume":"105","author":"MH Secrest","year":"2020","unstructured":"Secrest, M. H. et al. Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur. J. Haematol. 105, 173\u2013184 (2020).","journal-title":"Eur. J. Haematol."},{"key":"31571_CR2","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood-2017-10-810796","volume":"131","author":"RF Grace","year":"2018","unstructured":"Grace, R. F. et al. Clinical spectrum of pyruvate kinase deficiency: Data from the Pyruvate Kinase Deficiency Natural History Study. Blood 131, 2183\u20132192 (2018).","journal-title":"Blood"},{"key":"31571_CR3","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3324\/haematol.2019.241141","volume":"105","author":"P Bianchi","year":"2020","unstructured":"Bianchi, P. & Fermo, E. Molecular heterogeneity of pyruvate kinase deficiency. Haematologica 105, 2218\u20132228 (2020).","journal-title":"Haematologica"},{"key":"31571_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ajh.25753","volume":"95","author":"P Bianchi","year":"2020","unstructured":"Bianchi, P. et al. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am. J. Hematol. 95, 472\u2013482 (2020).","journal-title":"Am. J. Hematol."},{"key":"31571_CR5","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3324\/haematol.2019.240846","volume":"105","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari, H. et al. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica 105, 2229\u20132239 (2020).","journal-title":"Haematologica"},{"key":"31571_CR6","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1097\/HS9.0000000000000739","volume":"6","author":"NBA Roy","year":"2022","unstructured":"Roy, N. B. A. et al. The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A joint BSH\/EHA good practice paper. Hemasphere 6, e739 (2022).","journal-title":"Hemasphere"},{"key":"31571_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1365-2141.1983.tb02121.x","volume":"54","author":"S Takegawa","year":"1983","unstructured":"Takegawa, S., Fujii, H. & Miwa, S. Change of pyruvate kinase isozymes from M2- to L-type during development of the red cell. Br. J. Haematol. 54, 467\u2013474 (1983).","journal-title":"Br. J. Haematol."},{"key":"31571_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.10380","volume":"74","author":"S Aizawa","year":"2003","unstructured":"Aizawa, S. et al. Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. Am. J. Hematol. 74, 68\u201372 (2003).","journal-title":"Am. J. Hematol."},{"key":"31571_CR9","doi-asserted-by":"publisher","first-page":"e13890","DOI":"10.14814\/phy2.13890","volume":"6","author":"R Coffey","year":"2018","unstructured":"Coffey, R. et al. Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice. Physiol. Rep. 6, e13890 (2018).","journal-title":"Physiol. Rep."},{"key":"31571_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ajh.25613","volume":"94","author":"I Andolfo","year":"2019","unstructured":"Andolfo, I. et al. The BMP-SMAD pathway mediates the impaired hepatic iron metabolism associated with the ERFE-A260S variant. Am. J. Hematol. 94, 1227\u20131235 (2019).","journal-title":"Am. J. Hematol."},{"key":"31571_CR11","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz, L. et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia. Blood 126, 2031\u20132037 (2015).","journal-title":"Blood"},{"key":"31571_CR12","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood-2016-06-724328","volume":"128","author":"R Russo","year":"2016","unstructured":"Russo, R. et al. Increased levels of ERFE-encoding FAM132B in patients with congenital dyserythropoietic anemia type II. Blood 128, 1899\u20131902 (2016).","journal-title":"Blood"},{"key":"31571_CR13","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1097\/HS9.0000000000000627","volume":"5","author":"AJ van Vuren","year":"2021","unstructured":"van Vuren, A. J. et al. A comprehensive analysis of the erythropoietin-erythroferrone-hepcidin pathway in hereditary hemolytic anemias. Hemasphere 5, e627 (2021).","journal-title":"Hemasphere"},{"key":"31571_CR14","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood.V98.10.3113","volume":"98","author":"C Wang","year":"2001","unstructured":"Wang, C. et al. Human erythrocyte pyruvate kinase: Characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 98, 3113\u20133120 (2001).","journal-title":"Blood"},{"key":"31571_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ejh.13572","volume":"106","author":"AN Boscoe","year":"2021","unstructured":"Boscoe, A. N. et al. Comorbidities and complications in adults with pyruvate kinase deficiency. Eur. J. Haematol. 106, 484\u2013492 (2021).","journal-title":"Eur. J. Haematol."},{"key":"31571_CR16","doi-asserted-by":"publisher","first-page":"613559","DOI":"10.3389\/fphys.2020.613559","volume":"11","author":"R Russo","year":"2020","unstructured":"Russo, R., Marra, R., Rosato, B. E., Iolascon, A. & Andolfo, I. Genetics and genomics approaches for diagnosis and research into hereditary anemias. Front. Physiol. 11, 613559 (2020).","journal-title":"Front. Physiol."},{"key":"31571_CR17","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.exphem.2005.07.008","volume":"33","author":"S Aizawa","year":"2005","unstructured":"Aizawa, S. et al. Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity. Exp. Hematol. 33, 1292\u20131298 (2005).","journal-title":"Exp. Hematol."},{"key":"31571_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF02982790","volume":"76","author":"Y Kohgo","year":"2002","unstructured":"Kohgo, Y., Torimoto, Y. & Kato, J. Transferrin receptor in tissue and serum: Updated clinical significance of soluble receptor. Int. J. Hematol. 76, 213\u2013218 (2002).","journal-title":"Int. J. Hematol."},{"key":"31571_CR19","doi-asserted-by":"publisher","first-page":"9713","DOI":"10.3390\/ijms21249713","volume":"21","author":"C Richard","year":"2020","unstructured":"Richard, C. & Verdier, F. Transferrin receptors in erythropoiesis. Int. J. Mol. Sci. 21, 9713 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"31571_CR20","doi-asserted-by":"publisher","first-page":"E169","DOI":"10.1002\/ajh.23800","volume":"89","author":"R Russo","year":"2014","unstructured":"Russo, R. et al. Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: Definition of clinical and molecular spectrum and identification of new diagnostic scores. Am. J. Hematol. 89, E169\u2013E175 (2014).","journal-title":"Am. J. Hematol."},{"key":"31571_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bcmd.2010.11.001","volume":"46","author":"S Rocha","year":"2011","unstructured":"Rocha, S. et al. Complementary markers for the clinical severity classification of hereditary spherocytosis in unsplenectomized patients. Blood Cell Mol. Dis. 46, 166\u2013170 (2011).","journal-title":"Blood Cell Mol. Dis."},{"key":"31571_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1046\/j.1365-2141.1996.00285.x","volume":"92","author":"R Guarnone","year":"1996","unstructured":"Guarnone, R., Centenara, E., Zappa, M., Zanella, A. & Barosi, G. Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. Br. J. Haematol. 92, 150\u2013154 (1996).","journal-title":"Br. J. Haematol."},{"key":"31571_CR23","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/ijms23031304","volume":"23","author":"BE Rosato","year":"2022","unstructured":"Rosato, B. E. et al. SEC23B loss-of-function suppresses hepcidin expression by impairing glycosylation pathway in human hepatic cells. Int. J. Mol. Sci. 23, 1304 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"31571_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bjh.15758","volume":"184","author":"RF Grace","year":"2019","unstructured":"Grace, R. F., Layton, M. D. & Barcellini, W. How we manage patients with pyruvate kinase deficiency. Br. J. Haematol. 184, 721\u2013734 (2019).","journal-title":"Br. J. Haematol."},{"key":"31571_CR25","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/bloodadvances.2020001595","volume":"28","author":"AJ van Vuren","year":"2020","unstructured":"van Vuren, A. J. et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 28, 1678\u20131682 (2020).","journal-title":"Blood Adv."},{"key":"31571_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ajh.26247","volume":"96","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis. Am. J. Hematol. 96, 1064\u20131076 (2021).","journal-title":"Am. J. Hematol."},{"key":"31571_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjh.15811","volume":"185","author":"W Barcellini","year":"2019","unstructured":"Barcellini, W. et al. Iron overload in congenital haemolytic anaemias: Role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. Br. J. Haematol. 185, 523\u2013531 (2019).","journal-title":"Br. J. Haematol."},{"key":"31571_CR28","doi-asserted-by":"publisher","first-page":"E374","DOI":"10.1002\/ajh.25251","volume":"93","author":"S van Straaten","year":"2018","unstructured":"van Straaten, S. et al. Iron overload in patients with rare hereditary hemolytic anemia: Evidence-based suggestion on whom and how to screen. Am. J. Hematol. 93, E374\u2013E376 (2018).","journal-title":"Am. J. Hematol."},{"key":"31571_CR29","doi-asserted-by":"publisher","first-page":"e144206","DOI":"10.1172\/JCI144206","volume":"131","author":"A Matte","year":"2021","unstructured":"Matte, A. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u03b2-thalassemia mouse model. J. Clin. Investig. 131, e144206 (2021).","journal-title":"J. Clin. Investig."},{"key":"31571_CR30","doi-asserted-by":"publisher","first-page":"684569","DOI":"10.3389\/fphys.2021.684569","volume":"12","author":"E Fermo","year":"2021","unstructured":"Fermo, E. et al. Targeted next generation sequencing and diagnosis of congenital hemolytic anemias: A three years experience monocentric study. Front. Physiol. 12, 684569 (2021).","journal-title":"Front. Physiol."},{"key":"31571_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/genes12070958","volume":"23","author":"I Andolfo","year":"2021","unstructured":"Andolfo, I. et al. Complex modes of inheritance in hereditary red blood cell disorders: A case series study of 155 patients. Genes 23, 958 (2021).","journal-title":"Genes"},{"key":"31571_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ajh.25683","volume":"95","author":"I Andolfo","year":"2020","unstructured":"Andolfo, I. et al. Gain-of-function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP\/SMADs pathway. Am. J. Hematol. 95, 188\u2013197 (2020).","journal-title":"Am. J. Hematol."},{"key":"31571_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jclinepi.2021.08.001","volume":"142","author":"JC Digitale","year":"2022","unstructured":"Digitale, J. C., Marin, J. N. & Glymour, M. M. Tutorial on directed acyclic graphs. J. Clin. Epidemiol. 142, 264\u2013267 (2022).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31571-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:12:16Z","timestamp":1678968736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31571-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31571"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31571-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2276698\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PB, WB Agios Pharmaceuticals: advisory board member and consultancy; All the other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4395"}}